Howland Capital Management LLC Has $657000 Stake in Edwards Lifesciences Corp

Angelica Greene
May 19, 2017

Closing price generally refers to the last price at which a stock trades during a regular trading session.

A number of other large investors have also added to or reduced their stakes in EW. Meag Munich Ergo Kapitalanlagegesellschaft MBH purchased a new stake in Edwards Lifesciences Corp during the third quarter worth about $12,889,000. Sumitomo Life Insurance Co. increased its position in Edwards Lifesciences Corp by 41.2% in the third quarter. For the outlook of the current financial quarter, Analysts think the firm will post 0.88 earnings per share.

3/27/2017 - Edwards Lifesciences Corp was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. Fuller & Thaler Asset Management Inc. now owns 1,500 shares of the medical research company's stock worth $181,000 after buying an additional 700 shares during the last quarter.

Financial Engines Advisors Llc decreased Edwards Lifesciences Corp (EW) stake by 16.58% reported in 2016Q4 SEC filing. DnB Asset Management AS now owns 18,446 shares of the medical research company's stock valued at $2,224,000 after buying an additional 400 shares during the period. Advantage Investment Management LLC bought a new position in shares of Edwards Lifesciences Corp during the fourth quarter worth about $145,000. Insiders have sold 281,510 shares of company stock valued at $29,065,359 in the last 90 days. The company has Beta Value of 0.75 and ATR value of 2.02.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at 111.84 on Thursday. The firm exchanged a volume of 3.23 million shares at hands. The company has market cap of $23.63 billion. The stock is trading $99.21 its 50-day moving average by -14.44%. Integra Lifesciences Holdings Corp has a 52-week low of $35.33 and a 52-week high of $47.32.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.39 EPS for the quarter, missing analysts' consensus estimates of $0.40 by $0.01. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The firm had revenue of $883.50 million during the quarter, compared to analysts' expectations of $776.51 million. While in the same Quarter Previous year, the Actual EPS was $0.76. Edwards Lifesciences Corp's revenue was up 26.7% compared to the same quarter a year ago.

Ajax boss Peter Bosz hits back at Jose Mourinho
Jose Mourinho has confirmed Daley Blind could start for Manchester United in next week's Europa League final against Ajax . Southampton struggled to relieve the pressure building on manager Claude Puel against an under-strength United.

Trump says Russian Federation probe will reveal no collusion with his campaign
The person who described the Comey memo to the AP was not authorized to discuss it by name and spoke on condition of anonymity. He said he would give the Federal Bureau of Investigation a week and then "if we need a subpoena, we'll do it".

Chinese firms expected to make yearly investment of US$120bn-US$130bn
The minister, Delfin Lorenzana, said the Chinese government was offering a loan "at the tune of about $500 million" to finance the purchases.

ILLEGAL ACTIVITY WARNING: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of USA and global trademark and copyright law. Edwards Lifesciences Corp (NYSE:EW) has risen 6.00% since April 17, 2017 and is uptrending.

EW has been the subject of a number of recent research reports. Finally, Credit Suisse Group AG set a $120.00 target price on Edwards Lifesciences Corp and gave the stock a "buy" rating in a report on Wednesday, February 8th. Cowen and Company reiterated an "outperform" rating and issued a $120.00 target price on shares of Edwards Lifesciences Corp in a report on Tuesday, March 28th. The firm has "Overweight" rating given on Monday, April 4 by JP Morgan.

Shares of Edwards Lifesciences Corp (NYSE:EW) inclined 0.19% to $113.65. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. They now have a $127.00 price target on the stock.

On 5/15/2017 Patrick B. Verguet, VP, sold 11,500 with an average share price of $111.64 per share and the total transaction amounting to $1,283,860.00. The stock was sold at an average price of $45.91, for a total value of $636,542.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, the shares of the company have changed 27.00% and performed 24.88% over the last six months. The disclosure for this sale can be found here.

Investors who are keeping close eye on Kosmos Energy Ltd. (KOS) stock; watched recent volatility movements, they can see that shares have been recorded at 3.49% for the week, and 4.27% for the last month.

Edwards Lifesciences Corporation is a maker of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve.

Other reports by GizPress

Discuss This Article